Liquid biopsy-guided kidney-sparing management in upper tract urothelial carcinoma: from preoperative risk stratification to perioperative surveillance - Takeaways - MDSpire

Liquid biopsy-guided kidney-sparing management in upper tract urothelial carcinoma: from preoperative risk stratification to perioperative surveillance

  • By

  • Difei Yu

  • Jiarun Tang

  • Yu Zhang

  • Ke Hu

  • Jing Qing

  • Jiamo Zhang

  • June 2, 2026

  • 0 min

Share

  • 1

    Upper tract urothelial carcinoma (UTUC) accounts for 5-10% of urothelial cancers and often presents at an invasive stage.

  • 2

    Kidney-sparing surgery (KSS) is preferred for selected low-risk UTUC, while radical nephroureterectomy remains standard for high-risk cases.

  • 3

    Liquid biopsy platforms, including urine-based assays and plasma circulating tumor DNA, are emerging tools for preoperative risk assessment in UTUC.

  • 4

    Current evidence supports liquid biopsy as an adjunct to traditional imaging and pathology, not as a replacement.

  • 5

    Future studies should evaluate whether biomarker-informed pathways enhance treatment allocation and improve oncologic outcomes.

Original Source(s)

Liquid biopsy-guided kidney-sparing management in upper tract urothelial carcinoma: from preoperative risk stratification to perioperative surveillance

  • by Difei Yu, Jiarun Tang, Yu Zhang, Ke Hu, Jing Qing, Jiamo Zhang

  • June 2, 2026

Related Content

Case Report: A rare case of over 45 years’ survival in a patient with tonsillar adenoid cystic carcinoma

Digital Self-Management of Symptoms and Quality of Life for Patients With Advanced Cancer: A Randomized

ctDNA-guided precision therapy with trastuzumab deruxtecan plus pyrotinib in HER2-positive breast cancer brain metastases: a case report